BioSpace News Archive

Veeva Systems (NYSE: VEEV) today announced Veeva Vault CRM for Medtech , a unified customer relationship management (CRM) and content management application built for medtech sales team.

New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients Who Respond at the End of the Induction Period.

Novaliq Announces FDA Acceptance of the New Drug Application for CyclASol ® for the Treatment of Dry Eye Disease.

Castle Biosciences, Inc. today announced new data from UTILISE (Clinical Utili ty and Health Outcomes Study), a prospective, multi-center, clinical utility study of DecisionDx®-SCC, designed to capture the real-world impact of DecisionDx-SCC test results on the management of patients with cutaneous squamous cell carcinoma (cSCC) and one or more risk factors.

Enveric Biosciences Inc. today announced the nomination of EB-373 as the lead development candidate to emerge from its EVM201 program.

GenNext Technologies Wins the $250,000 Grand Prize at the BioTools Innovator Capstone Event.

Tricida, Inc. (NASDAQ: TCDA) announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer’s ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD).

Aclarion, Inc. announced today that Sigurd Berven M.D., Chief of Spine Service, Orthopaedic Surgery at University of California at San Francisco will advise the company as a key opinion leader (KOL) nationally.

Mallinckrodt plc today announced that five scientific abstracts on the clinical and health economic outcomes of treatment with TERLIVAZ.

IMJUDO® (tremelimumab) in Combination With IMFINZI® (durvalumab) Approved in the US for Patients With Unresectable Liver Cancer.